Gauraangana Trade Private Limited

Gauraangana Trade Private Limited, established on February 23, 2004, is a private limited company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51909DL2004PTC124792. Its authorized capital stands at ₹2.00 million, with a paid-up capital of ₹0.85 million. The registered office is located at 1851 Khari Baoli, New Delhi, Delhi, 110007.

Gauraangana Trade Private Limited operates in the wholesale trade and commission trade sector, excluding motor vehicles and motorcycles. The company is unlisted and has been active for over two decades. As of the latest available data, the company is led by two directors: Sandeep Goel and Sanjay Goel.

Specific details regarding Gauraangana Trade Private Limited's manufacturing facilities are not publicly disclosed. The company's export data indicates a focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, without explicit information on manufacturing locations and capacities, a comprehensive analysis cannot be provided.

The key executives of Gauraangana Trade Private Limited are:

• Sandeep Goel: Director since February 23, 2004.
• Sanjay Goel: Director since February 23, 2006.

No additional information regarding other key executives is available in the public domain.

Gauraangana Trade Private Limited's export data from 2022 to 2026 indicates shipments totaling $207,000 across 28 transactions, primarily involving finished pharmaceutical formulations. The top exported products include Dettol and Iodex, with market shares of 2.0% and 0.5%, respectively. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. Without explicit information on regulatory approvals and market access, a detailed analysis cannot be provided.

Gauraangana Trade Private Limited's export data does not specify shipments to Africa, Latin America, or Southeast Asia. The company's focus appears to be on finished pharmaceutical formulations, including products like Dettol and Iodex. Without explicit information on shipments to these regions or WHO prequalification status, a comprehensive analysis cannot be provided.

The export data indicates that Gauraangana Trade Private Limited's portfolio is entirely concentrated on two products: Dettol and Iodex, accounting for 100% of its exports. This suggests a high level of concentration risk. Without information on the company's strategic direction or diversification efforts, a detailed assessment of its geographic strategy cannot be provided.

Specific details regarding Gauraangana Trade Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. Without explicit information on these aspects, a comprehensive analysis of the company's FDA status cannot be provided.

There is no publicly available information regarding Gauraangana Trade Private Limited's WHO prequalification status, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. Without explicit details on these certifications, a thorough assessment cannot be conducted.

Specific information regarding Gauraangana Trade Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) is not publicly available. Without explicit details on these regulatory aspects, a comprehensive analysis cannot be provided.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with Gauraangana Trade Private Limited. Without explicit details on recent regulatory actions, a thorough assessment cannot be conducted.

Gauraangana Trade Private Limited's export data indicates a focus on finished pharmaceutical formulations, including products like Dettol and Iodex. However, without information on the company's competitors in overlapping categories, market share comparisons, or head-to-head analyses, a detailed competitive landscape assessment cannot be provided.

Gauraangana Trade Private Limited's export data highlights a concentration on two products: Dettol and Iodex. Without information on the company's unique strengths, competitive advantages, or product portfolio distinctions, a comprehensive analysis cannot be provided.

The export data indicates that Gauraangana Trade Private Limited's portfolio is entirely concentrated on two products, suggesting a high level of concentration risk. Without information on the company's strategic direction, such as a focus on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, a detailed assessment of its strategic position cannot be provided.

Gauraangana Trade Private Limited's export data indicates a focus on finished pharmaceutical formulations, including products like Dettol and Iodex. However, without information on the company's overall track record, export volume consistency, or reliability indicators, a comprehensive supplier assessment cannot be conducted.

Importers should verify the following certifications when considering Gauraangana Trade Private Limited as a supplier:

• FDA Registration: Confirm the company's FDA facility registration status.
• WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards.
• EU GMP Certification: Ensure the company holds valid European Union Good Manufacturing Practice certificates.
• ISO Certification: Check for relevant ISO certifications indicating quality management systems.

To verify each certification, contact the respective regulatory bodies or request copies of the certificates directly from Gauraangana Trade Private Limited.

When conducting due diligence on Gauraangana Trade Private Limited, consider the following steps:

• Verify Regulatory Certifications: Confirm the company's FDA registration, WHO-GMP, EU GMP, and ISO certifications.
• Assess Financial Health: Review the company's financial statements for profitability, revenue trends, and debt levels.
• Evaluate Product Portfolio: Analyze the concentration risk associated with the company's focus on two products.
• Check for Regulatory Compliance: Ensure the company complies with all relevant regulatory requirements in target markets.

Red flags to watch for include a lack of diversification in the product portfolio, absence of key regulatory certifications, and inconsistent financial performance. Recommended pre-order checks involve verifying the authenticity of certifications, assessing the company's reputation in the industry, and evaluating the quality control measures in place.